Bipolar Depression
Conditions
Keywords
Bipolar Disorder, Depression, Light Therapy, Contrast Sensitivity, Visual Evoked Potential, Visual or Neural Responses, Biomarker
Brief summary
Objective. Bipolar Disorders (BD) are a major public health problem. The investigators still lack knowledge of the mechanisms which contribute to BD. Hence treatments are few and limited, and clinical decision making is less refined. Currently, the investigators are investigating the effects of midday bright light therapy for the treatment of bipolar depression (University of Pittsburgh IRB approved protocol titled Light Therapy for Bipolar Disorder, IRB#: PRO09020546). In this study, the investigators propose to investigate a possible biological mechanism which might explain response to light treatment in depressed bipolar patients.
Detailed description
The study goal is to understand how the response to light therapy relates to changes in vision, brain function and improvement in bipolar symptoms. The aims are to investigate mood levels plus the eye and brain responses to visual contrast stimuli in healthy comparators (HC) and bipolar depressed patients. Study Design and Methods. Overview. The investigators plan to enroll 18-50 year old adults with BD Type I or II and a current episode of major depression on stable-dosed antimanic drugs, and age and sex-matched HC - without mental disorders. Depressed patients with BD will be assigned randomly to receive active light therapy vs inactive comparator for 6 weeks. The investigators will examine responses to contrast stimuli from measures of visual evoked potentials and electro-retinography in HC and depressed bipolar patients before and after 6-weeks of daily midday light therapy. The investigators will assess repeated measures of mood symptom levels, attention and circadian rhythms.
Interventions
None listed
Sponsors
University of Pittsburgh
Northwestern University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Ages 18-50 years. * DSM-IV BD Type I or II, current major depressive episode * Stable-dosed antidepressant drug for 4 weeks or more only with concurrent antimanic drug. * Controlled thyroid disease. * Subjects with preexisting eye diseases will be included specific exceptions are described in the
Exclusion criteria
. * Able to provide informed consent. * Stable minimum dose of antimanic drug for 4weeks or more. * Stable unchanged psychotherapy for 16 weeks or more. * Permitted drugs for sleep at low doses.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual evoked potentials (VEP) waveforms (mean amplitudes or latencies) | Week 0 and Week 6 | Visual Evoked Potential (VEP). This is a test which is used to assess visual cortical responses. The VEP recordings will be assessed at different contrast levels (80%, 16% and 7%) for the patient groups (BD vs HC). To assess the change in visual cortical responses, we will compare differences in the VEP responses between Weeks 0 and 6 between the groups. |
| Electroretinography (ERG) waveforms (mean amplitudes or latencies) | Week 0 and Week 6 | Electroretinogram (ERG). This is a test which is used to assess electrical responses of the retina. The ERG recordings will be assessed at different contrast levels (80%, 16% and 7%) for the patient groups (BD vs HC). To assess the change in retinal responses, we will compare differences in ERG responses between Weeks 0 and 6 between the groups. |
Countries
United States
Outcome results
None listed